title: Lenalidomide at therapeutic and supratherapeutic doses does not prolong QTc intervals in the thorough QTc study conducted in healthy men.
abstract: The effect of lenalidomide on the corrected QT (QTc) interval was evaluated in healthy men and extended to patients based on the lenalidomide concentration-QTc (C-QTc) relationship. A rigorous assessment of the effect of lenalidomide on QTc intervals was conducted in healthy volunteers who each received, in randomized order, a single oral dose of 10 mg lenalidomide, 50 mg lenalidomide, 400 mg moxifloxacin (positive control) and placebo. Plasma lenalidomide exposure was compared between healthy volunteers and patients with multiple myeloma or myelodysplastic syndromes. In healthy volunteers, moxifloxacin produced the expected significant prolongation in QTcI (individual correction). For lenalidomide 10 mg and 50 mg, the time-matched changes from placebo in the baseline-adjusted least-squares mean QTcI were <3 ms with the upper limit of the two-sided 90% confidence interval for the change <10 ms at all time-points. No subjects experienced QTcI >450 ms or change from baseline >60 ms after lenalidomide administration. Similar results were seen with QT interval data corrected by Fridericia and Bazett methods. The C-QTc analysis yielded no significant association between lenalidomide concentrations and QTcI changes up to 1522 ng/mL; this range was close to that observed in patients receiving lenalidomide doses up to 50 mg, including those with reduced drug clearance due to renal impairment. In conclusion, single doses of lenalidomide up to 50 mg were not associated with prolonged QTc intervals in healthy males. The C-QTc analysis further assured that lenalidomide doses up to 50 mg are not expected to prolong QTc intervals in patients.
authors: Department of Clinical Pharmacology, Celgene Corporation, Summit, NJ 07901, USA. nchen@celgene.com
authors: Nianhang
authors: N
authors: Chen
authors: Ying
authors: Y
authors: Ye
authors: Liangang
authors: L
authors: Liu
authors: Josephine
authors: J
authors: Reyes
authors: Mahmoud S
authors: MS
authors: Assaf
authors: Claudia
authors: C
authors: Kasserra
authors: Simon
authors: S
authors: Zhou
authors: Maria
authors: M
authors: Palmisano
mesh_terms: D000293:Adolescent; D000328:Adult; D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D001372:Aza Compounds / Q000494:pharmacology; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography; D024841:Fluoroquinolones; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D011804:Quinolines / Q000494:pharmacology; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000494:pharmacology; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D013792:Thalidomide; D000077269:Lenalidomide; D000077266:Moxifloxacin
references: Drugs. 1994 Jan;47(1):51-65
references: 7510621
references: Leukemia. 2009 Nov;23(11):2147-52
references: 19626046
references: Cancer Chemother Pharmacol. 2012 Nov;70(5):717-25
references: 22955172
references: Blood. 2008 Jun 1;111(11):5291-7
references: 18334676
references: Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):462-6
references: 21859554
references: J Clin Pharmacol. 2007 Dec;47(12):1466-75
references: 17954615
references: N Engl J Med. 2012 May 10;366(19):1759-69
references: 22571200
references: Br J Haematol. 2009 May;145(3):344-9
references: 19245430
references: Hum Psychopharmacol. 2012 Jan;27(1):39-42
references: 22144033
references: N Engl J Med. 2012 May 10;366(19):1782-91
references: 22571202
references: Br J Pharmacol. 2006 Nov;149(5):481-9
references: 16967046
references: N Engl J Med. 2007 Nov 22;357(21):2123-32
references: 18032762
references: N Engl J Med. 2007 Nov 22;357(21):2133-42
references: 18032763
references: Clin Pharmacol Ther. 2008 Oct;84(4):475-80
references: 19238652
references: Blood. 2002 Nov 1;100(9):3063-7
references: 12384400
references: Curr Drug Saf. 2010 Jan;5(1):93-6
references: 20210725
references: Cancer Chemother Pharmacol. 2009 May;63(6):1171-5
references: 19030860
references: N Engl J Med. 2012 May 10;366(19):1770-81
references: 22571201
references: N Engl J Med. 2006 Oct 5;355(14):1456-65
references: 17021321
references: Br J Clin Pharmacol. 1996 Feb;41(2):77-81
references: 8838432
references: J Cardiovasc Pharmacol. 2011 Jun;57(6):690-5
references: 21394035
references: J Anesth. 2013 Aug;27(4):575-87
references: 23412014
references: Lancet Oncol. 2010 Jan;11(1):29-37
references: 19853510
references: J Clin Pharmacol. 2010 Jul;50(7):767-74
references: 20160158
references: Blood. 2012 Oct 25;120(17):3419-24
references: 22936658
references: Cancer Chemother Pharmacol. 2012 Mar;69(3):789-97
references: 22037879
references: Ann Oncol. 2011 Jul;22(7):1622-1627
references: 21228334